Roquefort Therapeutics PLC MDK Oncology Antibodies Demonstrate In-Vivo Safety (5459N)
January 24 2023 - 2:00AM
UK Regulatory
TIDMROQ
RNS Number : 5459N
Roquefort Therapeutics PLC
24 January 2023
24 January 2023
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
MDK Oncology Antibodies Demonstrate In-Vivo Safety
Development milestone achieved
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market
listed biotech company focused on developing first in class
medicines in the high growth, high value oncology market is pleased
to announce the ROQ-A1 and ROQ-A2 Midkine ("MDK") antibody
programs, targeting metastatic breast cancer and metastatic lung
cancer, have successfully demonstrated in vivo safety in
pre-clinical development programs carried out by leading cancer
research groups.
As stated in the Company's announcement of 9 January 2023,
Roquefort Therapeutics has recently signed partnership agreements
and commenced pre-clinical development programs with leading
academic cancer research groups at the Olivia Newton-John Cancer
Research Institute (La Trobe University), Lowry Cancer Research
Centre (University of New South Wales), Hawkins Laboratory
Biochemistry and Genetics (La Trobe University) and the School of
Medical Sciences (University of Sydney).
ROQ-A1 and ROQ-A2 are the latest patented humanised antibody
medicines designed by Roquefort Therapeutics to target the novel
MDK target prevalent in hard-to-treat cancers. In laboratory
experiments, ROQ-A1 and ROQ-A2 bind highly specifically to the MDK
receptors in cancer cells to kill cancers in vitro.
The MDK antibody programs targeting metastatic breast cancer and
metastatic lung cancer commenced in Q4 2022 at La Trobe University,
Melbourne in the Olivia Newton-John Cancer Research Institute and
Hawkins Laboratory respectively and have now successfully reached
the first pre-clinical drug development milestone. Metastatic
breast cancer and metastatic lung cancer were chosen because of
high patient mortality rates (70% at five years) and prevalence of
resistant MDK subtypes which can reduce effectiveness of existing
therapies. Therefore, Roquefort Therapeutics is pleased that both
ROQ-A1 and ROQ-A2 have demonstrated a good safety profile in
validated in vivo models. These milestones were completed on
schedule and within budget.
Both MDK antibody programs will now progress into in vivo
pre-clinical efficacy studies to assess cancer killing ability in
primary and metastatic breast cancer and lung cancer. The Company
will update the market on the results of these efficacy studies as
they progress.
Ajan Reginald, Chief Executive Officer of Roquefort
Therapeutics, said:
"We have started 2023 with significant momentum successfully
completing these initial pre-clinical development milestones on
schedule and within budget. The ROQ-A1 and ROQ-A2 antibodies are
valuable assets that fit the established Big Pharma paradigm of
treating cancer with novel antibody therapeutics. Therefore, we are
pleased that both programs have shown the good safety profile that
is particularly attractive for innovative cancer medicines
targeting novel targets such as Midkine. Both programs will now
progress rapidly into in vivo pre-clinical efficacy testing. The
siRNA, MK cell therapy and Midkine oligonucleotide programs are
also progressing well and are expected to complete development
milestones in Q1, which we will update the market on in due
course."
-Ends-
Enquiries:
Roquefort Therapeutics plc
Stephen West (Chairman) / Ajan +44 (0)20 3918
Reginald (CEO) 8633
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Optiva Securities Limited (Joint +44 (0)203 764
Broker) 2341
+44 (0)20 3411
Christian Dennis 1881
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market
listed biotech company developing first in class drugs in the high
value and high growth oncology segment prior to partnering or
selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has
successfully acquired Lyramid Pty Limited, a leader in the
development of medicines for a new therapeutic target, Midkine (a
human growth factor associated with cancer progression), and most
recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor
Sir Martin Evans, which has developed two families of innovative
cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of four fully funded,
novel patent-protected pre-clinical anti-cancer medicines. The
highly complementary profile of four best-in-class medicines
consists of:
-- Midkine antibodies with significant in vivo efficacy and toxicology studies;
-- Midkine RNA therapeutics with novel anti-cancer gene editing action;
-- STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
-- MK cell therapy with direct and NK-mediated anti-cancer action.
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESBJMLTMTITMJJ
(END) Dow Jones Newswires
January 24, 2023 02:00 ET (07:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jul 2023 to Jul 2024